New Long-Acting drug for rare hormone tumors tested, but study stopped early
NCT ID NCT05364944
First seen Nov 17, 2025 · Last updated May 06, 2026 · Updated 27 times
Summary
This early-stage study tested a new formulation of octreotide (Debio 4126) that lasts 12 weeks, aiming to control hormone levels in people with acromegaly or certain neuroendocrine tumors. Only 19 participants were enrolled before the study was terminated. The goal was to measure how the drug behaves in the body and check its safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACROMEGALY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HM - Hôpital de la Conception, Service d'Endocrinologie et Centre de Référence des Maladies Rares de l'hypophyse
Marseille, 13385, France
-
AP-HP Hopital Bicetre
Le Kremlin-Bicêtre, 94270, France
-
CHU Angers
Angers, 49933, France
-
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano
Milan, 20122, Italy
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
Hospital de la Santa Creu i Sant Pau Barcelon
Barcelona, 08041, Spain
-
Mazowiecki Szpital Brodnowski - Zespol Oddzialow Chorob Wewnetrznych, Endokrynologii i Diabetologii
Warsaw, 03-242, Poland
-
Medicover Praxis fur Neuroendokrinologie
Munich, 81667, Germany
-
Rabin Medical Center, Beilinson Hospital, Clalit Health Services by Rabin Medical Center, Beilinson Hospita
Petah Tikva, 49100, Israel
-
Rigshospitalet, Endokrinologisk afdeling
Copenhagen, 2200, Denmark
-
Royal Free London NHS Foundation Trust
London, NW3 2QG, United Kingdom
-
Sheba Medical Center, Endocrine institute
Ramat Gan, 5265601, Israel
-
University Hospital Coventry, WISDEM Centre, UHCW NHS Trust
Coventry, CV2 2DX, United Kingdom
-
Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibinskiego Slaskiego Uniwersytetu Medycznego w Katowicach
Katowice, 40-514, Poland
Conditions
Explore the condition pages connected to this study.